KNSA insider filing: 39,364-share option grant and 15,091-share sale at $35.50
Rhea-AI Filing Summary
Kiniksa Pharmaceuticals (KNSA) Form 4 — Tessari Eben, Chief Operating Officer. The filing shows multiple equity awards and transactions between September 1–3, 2025. RSUs were granted/recorded totaling 9,828 RSUs on 09/01/2025 and additional RSUs from prior grants are reflected; each RSU converts to one Class A ordinary share. New stock options were granted on 09/01/2025 for 39,364 shares at a $33.49 exercise price and earlier vested options and RSUs remain outstanding. The reporting person sold 15,091 Class A shares on 09/03/2025 at a weighted average price of $35.50 and recorded additional small open-market sales on 09/01–09/02 at $33.49 and $34.28. Post-transactions beneficial ownership totals are reported in the range of 43,438 to 59,543 Class A shares depending on line items.
Positive
- Long-term incentive alignment: Grant of a 39,364-share option at $33.49 and multiple RSUs vesting over four years links executive pay to future share performance.
- Use of 10b5-1 plan: Some sales were executed pursuant to a pre-established 10b5-1 trading plan, reducing concerns about opportunistic insider timing.
Negative
- Insider sale: The reporting person sold 15,091 shares on 09/03/2025 at a weighted average price of $35.50, modestly reducing insider ownership.
- Potential dilution: Outstanding options and RSUs (including 39,364 option shares and multiple RSU grants) represent future dilution if exercised/settled.
Insights
TL;DR: Routine executive compensation activity with contemporaneous open-market sales under a 10b5-1 plan; not a material corporate event.
The Form 4 documents standard equity compensation and insider selling activity by the COO. Grants include RSUs that vest over multiple years and a sizable option grant exercisable at $33.49, which aligns management incentives with shareholder value over the option term. The sale of 15,091 shares was executed under a broker and partially under a 10b5-1 plan, indicating pre-planned divestiture rather than opportunistic trading. Overall, this filing reflects compensation realization and liquidity moves rather than operational or governance changes.
TL;DR: Mix of awards and sales; option and RSU grants increase potential dilution while an open-market sale slightly reduces insider holdings.
The grant of a 39,364-share option at $33.49 and multiple RSU issuances increase the COO's long-term upside exposure but also represent potential future dilution if exercised. The exercised/vested items and the 15,091-share sale at a weighted $35.50 provide the executive with liquidity. The sale prices reported ($33.49, $34.28, $35.50) are near the option strike, suggesting exercise economics are modestly in-the-money for some tranches. For investors, this is a routine disclosure of compensation and personal trading, with limited immediate impact on company fundamentals.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Share Option | 65 | $0.00 | -- |
| Exercise | Share Option | 15,026 | $0.00 | -- |
| Exercise | Class A Ordinary Share | 65 | $15.52 | $1K |
| Exercise | Class A Ordinary Share | 15,026 | $15.50 | $233K |
| Sale | Class A Ordinary Share | 15,091 | $35.50 | $536K |
| Exercise | Restricted Share Unit | 1,964 | $0.00 | -- |
| Exercise | Class A Ordinary Share | 1,964 | $0.00 | -- |
| Tax Withholding | Class A Ordinary Share | 950 | $34.28 | $33K |
| Grant/Award | Restricted Share Unit | 9,828 | $0.00 | -- |
| Grant/Award | Share Option | 39,364 | $0.00 | -- |
| Exercise | Restricted Share Unit | 1,746 | $0.00 | -- |
| Exercise | Restricted Share Unit | 1,773 | $0.00 | -- |
| Exercise | Restricted Share Unit | 2,726 | $0.00 | -- |
| Exercise | Class A Ordinary Share | 1,746 | $0.00 | -- |
| Exercise | Class A Ordinary Share | 1,773 | $0.00 | -- |
| Exercise | Class A Ordinary Share | 2,726 | $0.00 | -- |
| Tax Withholding | Class A Ordinary Share | 3,022 | $33.49 | $101K |
Footnotes (1)
- Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 29, 2024. This transaction was executed in multiple trades through a broker-dealer at prices ranging between $35.50 and $35.53. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date September 1, 2025. The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2025. The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date September 1, 2024. The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2023. The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2022. The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the vesting commencement date September 2, 2021. The option is fully vested and exercisable.
